India’s probiotics market doubles in five years, hits Rs. 2,070 crore (US$ 242 million) in 2025

With a growing consumer focus on gut health, immunity, and digestion, probiotics are becoming a key part of Indian diets. According to PharmaTrac, the probiotics market in India registered a strong 22% growth on a Moving Annual Total (MAT) basis for May 2025. The market has nearly doubled in five years, rising from Rs. 1,016 crore (US$ 118.90 million) in 2021 to Rs. 2,070 crore (US$ 242 million) in 2025. Pharmaceutical companies such as Sun Pharmaceutical Industries, USV, Zydus Lifesciences, Torrent Pharmaceuticals, Mankind Pharma, and Dr. Reddy’s Laboratories continue to dominate the market, with older brands leading growth. New launches in the last two years have contributed only Rs. 49 crore (US$ 5.73 million) in revenue.

Probiotic drugs make up over 90% of the Indian market, followed by milk-based products. Dairy firms like Amul and Mother Dairy are pushing aggressively in this segment, while start-ups such as The Good Bug and WellBeing Nutrition are attracting investor interest. Amul claims to be the country’s largest probiotic brand, selling three million litres of probiotic buttermilk daily. The category remains under-penetrated but is growing in high double digits, supported by increasing health awareness and social media influence, especially among the youth. However, experts warn against indiscriminate use. While probiotics are effective in managing specific gut disorders, their broad use in unrelated conditions may be unwarranted. The overall market has recorded a five-year compound annual growth rate of 19%, with May’s performance underlining strong consumer demand for gut-health-focused solutions.

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.